Remdesivir reduces hospital stay, doesn't show benefit in mortality: AIIMS

AIIMS Director Dr Randeep Guleria explained the ways in which Covid-19 patients are being treated

coronavirus, COVID 19, lockdown
(FILE PIC) Health workers collect swab samples from people for Covid-19 tests in New Delhi | Photo: PTI
ANI New Delhi
2 min read Last Updated : Jun 13 2020 | 12:29 PM IST
Remdesivir helps decrease hospital stay but the benefits don't reflect as far as death or mortality is concerned, All India Institute of Medical Sciences (AIIMS) New Delhi Director Dr Randeep Guleria said on Friday.

"There is no definite anti-viral drug which has been proved as far as Covid-19 is concerned. A lot of research is going on. There are some anti-viral drugs which are being used, one of them is 'Remdesivir' that is being made by a company from the US. Data suggests that it helps to decrease hospital stay but it doesn't show benefit as far as death or mortality benefit is concerned. So we need more data to suggest that these drugs are useful or not," said Dr Guleria in an interview to ANI.


"Remdesivir is used as per the guidelines of emergency use authorisation. There is also very limited stock available. I am hopeful that in coming weeks we have larger doses of it," he added.

Dr Guleria explained about the ways in which Covid-19 patients are being treated. He said that hydroxychloroquine (HCQ) is the commonly used drugs to treat the patients.


"Repurposed drugs are available in the market and studies, too, have suggested that they may have anti-viral activities and therefore they can be used. The drug which we use commonly for treating coronavirus patients is hydroxychloroquine (HCQ). There are controversies regarding the drug but data suggests that it may be useful especially in the early days," he said.

He further spoke about the convalescent plasma therapy in which we give plasma having antibodies from the people who have recovered to the affected patient so that these antibodies help in fighting against the virus.

"These are still evolving treatments and some may be useful and some may not be that useful. But treatment currently remains supportive care oxygenation. As many as 90 to 95 per cent patients with good supportive care oxygenation actually recovery and become alright," he added.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusAIIMSLockdownmortality rate

Next Story